Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 20 of 23

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract May 2006

Standard vs. Reduced Dose Systemic Bevacizumab (Avastin®) for the Treatment of Neovascular Age–Related Macular Degeneration

S.M. Michels; P.J. Rosenfeld; W. Geitzenauer; F. Prager; A. Rosin; G. Kornek; L. Vormittag; U. Schmidt–Erfurth

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):5231.

ARVO Annual Meeting Abstract May 2006

Intravitreal Avastin Safety Survey: Results From the World Wide Web

A.E. Fung; P.J. Rosenfeld; E.Z. Reichel

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):5251.

ARVO Annual Meeting Abstract May 2006

Optical Coherence Tomography Findings in a Variable–Dosing Regimen with Ranibizumab (LucentisTM): The PrONTO Study

G. Lalwani; A.E. Fung; S. Michels; A.S. Venkatraman; C.A. Puliafito; P.J. Rosenfeld

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):2147.

ARVO Annual Meeting Abstract May 2006

Visual Acuity Outcomes Following a Variable–Dosing Regimen for Ranibizumab (LucentisTM) in Neovascular AMD: The PrONTO Study

P.J. Rosenfeld; A.E. Fung; G.A. Lalwani; S. Michels; A.S. Venkatraman; C.A. Puliafito

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):2958.

ARVO Annual Meeting Abstract May 2005

Non–infectious Pseudohypopyon Following Intravitreal Triamcinolone Acetonide (IVTA) Injection

H.W. Flynn; A.A. Moshfeghi; J.L. Davis; J.W. Kitchens; T.G. Murray; C.A. Puliafito; P.J. Rosenfeld; I.U. Scott; W.E. Smiddy

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):486.

ARVO Annual Meeting Abstract May 2005

3–D OCT Maps of Retinal Pathologies

G. Gregori; R.W. Knighton; S. Jiao; X. Huang; P.J. Rosenfeld; C.A. Puliafito

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1055.

ARVO Annual Meeting Abstract May 2005

Optical Coherence Tomography (OCT) Outcomes Following Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration

C.A. Puliafito; P.J. Rosenfeld; S. Michels; A.A. Moshfeghi; A.E. Fung; K.D. Rosenberg; A.S. Venkatraman

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1376.

ARVO Annual Meeting Abstract May 2005

Indocyanine Green Angiographic Outcomes Following Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration

K.D. Rosenberg; P.J. Rosenfeld; C.A. Puliafito; S. Michels; A.A. Moshfeghi; A.E. Fung

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1377.

ARVO Annual Meeting Abstract May 2005

Safety of Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration

S.M. Michels; P.J. Rosenfeld; C.A. Puliafito; A.A. Moshfeghi; A.E. Fung; K.D. Rosenberg; E.N. Marcus; A.S. Venkatraman

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1378.

ARVO Annual Meeting Abstract May 2005

Durability of Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration

A.A. Moshfeghi; P.J. Rosenfeld; C.A. Puliafito; S. Michels; A.E. Fung; K.D. Rosenberg; A.S. Venkatraman

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1381.

ARVO Annual Meeting Abstract May 2005

Fluorescein Angiographic Outcomes Following Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration

A.E. Fung; P.J. Rosenfeld; C.A. Puliafito; S. Michels; A.A. Moshfeghi; K.D. Rosenberg; E.N. Marcus; A.S. Venkatraman

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1382.

ARVO Annual Meeting Abstract May 2005

Long–Term Experience With LucentisTM (Ranibizumab) in Patients With Neovascular Age–Related Macular Degeneration (AMD)

J.S. Heier; P.J. Rosenfeld; A.N. Antoszyk; G. Hantsbarger; R. Kim; N. Shams

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1393.

ARVO Annual Meeting Abstract May 2005

Systemic Bevacizumab (Avastin®) Therapy for Neovascular Age–Related Macular Degeneration (SANA) Study: Visual Acuity Outcomes

P.J. Rosenfeld; C.A. Puliafito; S. Michels; A.A. Moshfeghi; A.E. Fung; K.D. Rosenberg; E.N. Marcus; A.S. Venkatraman

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):2310.

ARVO Annual Meeting Abstract May 2004

Intravitreal triamcinolone for the treatment of macular edema from central retinal vein occlusion

J.E. Lee; E.C. Mavrofrides; W.E. Smiddy; I.U. Scott; P.J. Rosenfeld; H.W. Flynn Jr; T.G. Murray; A.M. Berrocal; C.A. Puliafito

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):5238.

ARVO Annual Meeting Abstract May 2004

Verteporfin In Minimally Classic CNV due to AMD (VIM) – Two–Year Results from a Phase II Controlled Clinical Trial

P.J. Rosenfeld; VIM Study Group

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):2273.

ARVO Annual Meeting Abstract May 2004

Verteporfin with Altered (Delayed) Light In Occult (VALIO) – 12–Month Results of a Phase II Controlled Clinical Trial

L.J. Singerman; P.J. Rosenfeld; VALIO Study Group

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):2274.

ARVO Annual Meeting Abstract May 2004

Comparing total macular volume changes measured by Optical Coherence Tomography with retinal lesion volume estimated by active contours.

D. Cabrera Fernández; N. Villate; C.A. Puliafito; P.J. Rosenfeld

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):3072.

ARVO Annual Meeting Abstract May 2004

Verteporfin Therapy of Juxtafoveal Lesions in Patients with Neovascular AMD

D.L. Barker; C.A. Puliafito; P.J. Rosenfeld

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):3158.

ARVO Annual Meeting Abstract May 2004

Verteporfin Therapy with Intravitreal Triamcinolone in Patients with Neovascular AMD

A.A. Moshfeghi; C.A. Puliafito; P.J. Rosenfeld

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):3159.

ARVO Annual Meeting Abstract May 2003

A Phase II Placebo-Controlled, Double-Masked, Randomized Trial - Verteporfin in Minimally Classic CNV Due to AMD (VIM)

N.M. Bressler; P.J. Rosenfeld; J.I. Lim; VIM Study Group

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):1100.

1 2

Next 20 Results »

Advertisement